Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors

Journal of Virology

Volumn 71, Issue 2, 1997, Pages 1089-1096

  Croteau, Gilbert ^a   Doyon, Louise ^a   Thibeault, Diane ^a   Mckercher, Ginette ^a   Pilote, Louise ^a   Lamarre, Daniel ^a  

^a BOEHRINGER INGELHEIM CANADA LTD   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE; PROTEINASE INHIBITOR; VIRUS ENZYME;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVE SITE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; THERAPY RESISTANCE; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0031015475     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.71.2.1089-1096.1997     Document Type: Article

References (43)

1. Adachi, A., H. E. Gendelman, S. Koenig, T. Folks, R. Willey, A. Rabson, and M. A. Martin. 1986. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 59:284-291.
2. Condra, J., H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, A. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
3. Croteau, G., L. Doyon, and D. Lamarre. Unpublished data.
4. Darke, P. L., and J. R. Huff. 1994. HIV protease as an inhibitor target for the treatment of AIDS. Adv. Pharmocol. 25:399-454.
5. Darke, P. L., R. F. Nutt, S. F. Brady, V. M. Garsky, T. M. Ciccarone, C. H. Leu, P. K. Lumma, R. M. Freidinger, D. F. Veber, and I. S. Sigal. 1988. HIV-1 protease specificity of peptide cleavage is sufficient for processing of Gag and Pol polyproteins. Biochem. Biophys. Res. Commun. 156:297-303.
6. De Clerq, E. 1992. HIV inhibitors targeted at the reverse transcriptase. AIDS Res. Hum. Retroviruses 8:119-134.
7. Doyon, L., G. Croteau, D. Thibeault, F. Poulin, L. Pilote, and D. Lamarre. 1996. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol 70:3763-3769.
8. Erice, A., and H. H. Balfour, Jr. 1994. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin. Infect. Dis. 18: 149-156.
9. Erickson, J. W. 1995. The not-so-great escape. Nat. Struct. Biol. 2:523-529.
10. Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J, W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34: 9282-9287.
11. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
12. Ho, D. D., T. Toyoshima, H. Mo, D. J. Kempt, D. Norbeck, C. M. Chen, N. E. Wideburg, S. K. Burt, J. W. Erickson, and M. K. Singh. 1994. Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J. Virol 68:2016-2020.
13. Kaplan, A. H., S. F. Michael, R. S. Wehbie, M. F. Knigge, D. A. Paul, L. Everitt, D. J. Kempf, D. W. Norbeck, J. W. Erickson, and R. Swanstrom. 1994. Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease. Proc. Natl. Acad. Sci. USA 91:5597-5601.
14. Kimberlin, D. W., D. M. Coen, K. K. Biron, J. I. Cohen, R. A. Lamb, M. McKinlay, E. A. Emini, and R. J. Whitley. 1995. Molecular mechanisms of antiviral resistance. Antiviral Res. 26:369-401.
15. Kohl, N. E., E. A. Emini, W. A. Schleif, L. J. Davis, J. C. Heimbach, R. A. F. Dixon, E. M. Scolnick, and I. S. Sigal. 1988. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85:4686-4690.
16. Lamarre, D., G. Croteau, L. Bourgon, D. Thibeault, E. Wardrop, C. Clouette, M. Vaillancourt, E. Cohen, C. Pargellis, C. Yoakim, and P. C. Anderson. Antiviral properties of palinavir. a potent inhibitor of the human immunodeficiency virus type-1 (HIV-1) protease. Submitted for publication.
17. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in the HIV-1 reverse transcriptase confer high-level resistance to Zidovudine (AZT). Science 246:1155-1158.
18. Lin, Y., X. Lin, L. Hong, S. Foundling, R. L. Heinrikson, S. Thaisrivongs, W. Leelamanit, D. Raterman, M. Shah, B. M. Dunn, and J. Tang. 1995. Effect of point mutations on the kinetics and the inhibition of human immunodeficicency virus type I protease: relationship to drug resistance. Biochemistry 34:1143-1152.
19. Lynn, D. E. 1992. A basic computer program for analyzing endpoint assays. BioTechniques 12:880-881.
20. Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat. J. W. Erickson, and D. D. Ho. 1995. Selection analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706.
21. Mellors, J. W., B. A. Larder, and R. F. Schinazi. 1995. Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 3:8-13.
22. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
23. Morrison, J. F., and C. T. Walsh. 1988. The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. 61:201-301.
24. Pargellis, C. A., M. M. Morelock, E. T. Graham, P. Kinkade, S. Pav, K. Lubbe, D. Lamarre, and P. C. Anderson. 1994. Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer. Biochemistry 33:12527-12534.
25. Partaledis, J. A., K. Yamaguchi, M. Tisdale, E. E. Blair, C. Falcione, B. Maschera, R. E. Myers, S. Pazhanisamy, O. Futer, A. B. Cullinan, C. M. Stuver, R. A. Byrn, and D. J. Livingston. 1995. In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J. Virol. 69:5228-5235.
26. Patick, A. K., R. Rose, J. Greytok, C. M. Bechtold, M. A. Hermsmeier, P. T. Chen, J. C. Barrish, R. Zahler, R. J. Colonno, and P. F. Lin. 1995. Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J. Virol. 69:2148-2152.
27. Pav, S., K. Lubbe, F. Dô, D. Lamarre, C. Pargellis, and L. Tong. 1994. Microtube batch protein crystallization: applications to human immunodeficiency virus type 2 (HIV-2) protease and human renin. Protein Struct. Funct. Genet. 20:98-102.
28. Peng, C., B. K. Ho. T. W. Chang, and N. T. Chang. 1989. Role of human immunodeficiency virus type 1-specific protease in core maturation and viral infectivity. J. Virol. 63:2550-2556.
29. Pettit, S. C., S. F. Michael, and R. Swanstrom. 1993. The specificity of the HIV-1 protease. Perspect. Drug Discov. Design 1:69-83.
30. Popovic, M., E. Read-Connole, and R. C. Gallo. 1984. T4 positive human neoplastic cell lines susceptible to and permissice for HTLV-III. Lancet ii:1472-1473.
31. Popovic, M., M. G. Sarngadharan, E. Read, and R. C. Gallo. 1984. Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 224:497-500.
32. Preston, B. D., B. J. Poiesz, and L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
33. Ratner, L., W. Haseltine, R. Patarca, K. J. Livak, B. Starcich, S. F. Josephs, E. R. Doran, J. A. Rafalski, E, A. Whitehorn, E. Baumeister, L. Ivanoff, S. R. Petteway Jr., M. L. Pearson, J. A. Lautenberger, T. S. Papas, J. Ghrayab, N. T. Chang, R. G. Gallo, and F. Wong-Staal. 1985. Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature 313:277-283.
34. Rosé, J. R., L. M. Babe, and C. S. Craik. 1995. Defining the level of human immunodeficiency virus type 1 (HIV-1 ) protease activity required for HIV-1 particle maturation and intectivity. J. Virol. 69:2751-2758.
35. Rose, R. E., Y. F. Gong, J. A. Greytok, C. M. Bechtold, B. J. Terry, B. S. Robinson, M. Alam, R. J. Colonno, and P. F. Lin. 1996. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. Sci. USA 93:1648-1653.
36. Sardana, V. V., A. J. Schlabach, P. Graham, B. L. Bush, J. H. Condra, J. C. Culberson, L. Gotlib, D. J. Graham, N. E. Kohl, R. L. LaFemina, C. L. Schneider, B. S. Wolanski, J. A. Wolfgang, and E. A. Emini. 1994. Human immunodeficiency virus type 1 protease inhibitors: evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry 33:2004-2010.
37. Tantillo, C., J. Ding, A. Jacobo-Molina, R. G. Nanni, P. L. Boyer, S. H. Hughes, R. Pauwels, K. Andries, P. A. Janssen, and E. Arnold. 1994. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. J. Mol. Biol. 243:369-387.
38. Tong, L., S. Pav, S. Mui, D. Lamarre, C. Yoakim, P. Beaulieu, and P. C. Anderson. 1995. Crystal structures of HIV-2 protease in complex with inhibitors containing the hydroxyethylamine dipeptidyl isostere. Structure 3:33-40.
39. Toth, M. V., and G. R. Marshall. 1990. A simple, continuous fluorometric assay for HIV protease. Int. J. Peptide Protein Res. 36:544-550.
40. Tozser, J., I. Blahah, T. D. Copeland, E. M. Wondrak, and S. Oroszlan. 1991. Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins. FEBS Lett. 281:77-80.
41. Wei, X., S. K. Ghosh, M. E. Taylor, V. A. Johnson, E. A. Emini, P. Deutsch, J. D. Lifson, S. Bonhoeffer, M. A. Nowak. B. H. Hahn, M. S. Saag, and G. M. Shaw. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373:117-122.
42. West, M. L., and D. P. Fairlie. 1995. Targeting HIV-1 protease: a test of drug-design methodologies. Trends Pharmacol. Sci. 16:67-75.
43. Wondrak, E. M., J. M. Louis, H. de Rocquigny, J. C. Chermann, and B. P. Roques. 1993. The Gag precursor contains a specific HIV-1 protease cleavage site between the NC (p7) and p1 proteins. FEBS Lett. 333:21-24.